JARA Scientist Prof. Dieter Willbold Guides Alzheimer Medication PRI-002 into Phase II Trial

The Alzheimer drug candidate PRI-002 is advancing to the next phase of testing: The European Medicines Agency (EMA) has granted approval for a clinical Phase II trial. This marks the first time the drug candidate will be tested on a larger group of Alzheimer patients. The development of this drug was carried out under the guidance and at the institute of JARA scientist Prof. Dieter Willbold. In September 2017, Priavoid GmbH was established, stemming from the Jülich Research Center, to shepherd the drug towards market readiness.

The goal of the study is to evaluate the effectiveness of PRI-002 in patients in the early stages of Alzheimer's disease. The drug candidate will be tested in a placebo-controlled Phase II trial involving 270 patients across initially six European countries. The safety of PRI-002 for both healthy volunteers and patients has already been successfully demonstrated in three Phase I trials over the past years.

For more information on this topic, please visit the website of the Jülich Research Center: https://www.fz-juelich.de/de/aktuelles/news/pressemitteilungen/2023/alzheimer-medikament-pri-002-phase-ii